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Orthopaedic patients are at the highest risk among all patients for venous 
thromboembolism (VTE) in terms of perioperative complications. Without any prophylaxis the 
incidence of deep vein thrombosis ranges from 40% to 60% in patients after major orthopaedic 
surgeries and the incidence of fatal pulmonary embolism is 2% to 3% after elective total hip 
replacement (THR). The ideal method of VTE prophylaxis remains controversial. Recently the 
new, direct oral anticoagulants (DOACs) for THR have become attractive methods for VTE 
prevention. Perioperative anticoagulation, although useful for reducing the significant risk of 
VTE, on the other side of the haemostatic equilibrium, all forms of pharmacological 
prophylaxis inevitably increase the perioperative bleeding rate. Several studies have proven the 
blood loss reducing effect of perioperatively administered antifibrinolytic tranexamic acid 
(TXA), which has become part of perioperative protocols in THR. Development trials with 
DOACs investigated the major and clinically significant bleeding events as safety endpoints, 
however, minor bleeding events and wound complications were largely neglected. Most of the 
studies with TXA describing its blood loss reducing effect used low molecular weight heparins 
(LMWHs) for VTE prophylaxis. Only very few studies are known to examine TXA’s beneficial 
effect when the new DOACs are used as perioperative anticoagulants. Studies with TXA also 
neglected to explore its effect on minor bleeding and wound complications. 
Our aim was to evaluate the incidence of minor bleeding complications, soft-tissue 
adverse effects and intraoperative blood loss using DOACs and TXA following cemented THR.  
In Study I, consecutive patients were enrolled, who underwent primary cemented THR. 
Two groups were formed according to the used perioperative anticoagulant. Patients were 
allocated to enoxaparin (LMWH) group and to dabigatran (DOACs) group. Thigh volume 
changes, calculated perioperative blood loss, area of haematoma, wound bleeding, duration of 
wound discharge and intensity of serous wound discharge on the 3rd and 7th postoperative day 
were examined. We found the same, statistically significant increase in thigh volume in both 
groups between the initial and 7th postoperative day data, without any difference in thigh 
volumes with the two different anticoagulants. The calculated perioperative blood loss was the 
same in both groups. The duration and intensity of serous wound discharge differed 
significantly between the two groups. Duration of wound discharge after drain removal was 2.2 
5 
(± 2.7) days in the dabigatran group and 1.2 (± 1.9) days in the enoxaparin group (p<0.05). 
Significant increase in serous discharge was found in the dabigatran group (p<0.05) on the 3rd 
and 7th postoperative days comparing to the enoxaparin group. 
In Study II, we assessed the efficacy of TXA in reducing minor bleeding complications, 
when rivaroxaban was used for thromboprophylaxis. Consecutive patients undergoing primary 
cemented THR were studied prospectively. Patients received TXA perioperatively between 
January 2014 and November 2014 designated as TXA group. We compared this data to a group 
of patients who underwent the same procedure, between February 2012 and December 2012 
(control group), before the introduction of TXA. We investigated the effect of TXA on surgical 
wound bleeding and wound discharge, area of hematoma on the skin surface, thigh volume 
changes, calculated perioperative blood loss and transfusion requirement. The extent of 
postoperative thigh swelling was significantly less in the TXA group 270.3 mL (129.1-449.0) 
as compared with the control group 539.8 mL (350.0-864.8, p<0.001). TXA significantly 
reduced wound bleeding during the first 24 hours postoperatively (p<0.001). The amount of 
calculated perioperative blood loss was significantly less in the TXA group (p<0.001). The area 
of haematoma was significantly smaller in the TXA group (p<0.001). Transfusion requirement 
was remarkable lower in the TXA group (15%, total 26 units vs. 39%, total 82 units). 
Based on our studies we can conclude that dabigatran has the same appropriate 
antithrombotic effects after THR comparing to enoxaparin. However, the use of dabigatran is 
associated with an increased incidence of prolonged discharge from the drain site and elevated 
amount of serous wound discharge. TXA significantly reduces postoperative thigh volume, 
wound bleeding and area of hematoma on the skin when rivaroxaban is used as the 
anticoagulant. Further large scale studies could help establish the clinical relevance and long-
term outcome of minor bleeding complications. 
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In the 1960’s, Sir John Charnley developed the basic principles of modern low friction 
cemented total hip replacement (THR). THR is one of the most commonly performed 
orthopaedic procedures, with hundreds of thousands of operations performed each year [1]. It 
can greatly improve the quality of life for patients with end-stage degenerative disease of the 
hip. The competing risks of thrombotic events and haemorrhagic complications are amongst 
the major concerns following hip replacement. Perioperative thrombotic complications are a 
major causes of morbidity and mortality. On the opposite end of the haemostatic equilibrium, 
perioperative bleeding increases the risk of reoperation, infection, overall length of stay, and 
hospital costs [2]. 
Venous thromboembolism (VTE) is a common complication during and after 
hospitalization for medical, surgical and especially orthopaedic patients. More than half of all 
hospitalized patients are at risk for VTE. Generally speaking, the surgical patients are at an 
increased risk compared with medical patients and orthopaedic patients are at an even higher 
risk of postoperative thrombotic complications [3]. Without any prophylaxis the incidence of 
deep vein thrombosis (DVT) in medical and general surgical patients is in the range of 10% to 
40%; in comparison, the incidence of DVT ranges from 40% to 60% in patients after major 
orthopaedic surgeries [4, 5]. Similarly, the incidence of fatal pulmonary embolism (PE) in 
hospitalized patients is 0.1% to 0.8% after elective general surgery, whilst it is 2% to 3% after 
elective hip replacement. Death within one month of diagnosis occurs in approximately 6% of 
DVT patients and approximately 12% of PE patients [6, 7]. 
Orthopaedic patients are at the highest risk among all patients for VTE in terms of 
perioperative complications. In the 19th century Virchow described the three factors that affect 
coagulation within a blood vessel. The factors included in Virchow’s triad are the stasis or 
stoppage of blood flow, vascular endothelial damage and hypercoagulability of blood. Risk 
factors, which relate to these factors, can predict which patients will be most likely to develop 
VTE complications. In an orthopaedic patient during the perioperative period, all of the above 
mentioned pathophysiologic processes are frequently present: 1) use of tourniquet, 
immobilization and bed rest cause venous blood stasis; 2) surgical manipulation of the limb 
cause endothelial vascular injuries; 3) trauma increases the number of thromboplastin agents; 
9 
and 4) use of polymethylmethacrylate bone cement increase hypercoagulability [8]. Therefore, 
in patients undergoing orthopaedic surgery VTE prophylaxis and adherence to the respective 
guidelines are of paramount importance [9]. Although there are many national and international 
thromboprophylaxis guidelines, which have recommended thromboprophylaxis for patients 
admitted to the hospital, only 60% to 75% of surgical patients actually receive adequate 
thromboprophylaxis [8-12].  
Perioperative anticoagulation, although useful for reducing and preventing the significant 
risk of VTE after orthopaedic surgery, on the other side of the haemostatic equilibrium, all 
forms of pharmacological prophylaxis increase the risk of perioperative bleeding complications 
[13]. Major perioperative bleeding increases the risk of reoperation, length of stay, and hospital 
costs. Severe anaemia (haemoglobin <8 mg/dL) is associated with increased postoperative 
mortality and poor functional recovery. Allogeneic blood transfusion is a traditional and 
frequently used method to treat a patient’s low and symptomatic postoperative haemoglobin 
(Hb) level, however it is well known, that it can potentially extend the rehabilitation time and 
the length of hospital stay and has a number of potential adverse effects [14]. In addition to this, 
transfusion inhibits the immune system and increases the chance of infection. Various methods 
are available for both orthopaedic surgeons and anaesthesiologists to reduce perioperative blood 
loss and prevent the need for allogeneic blood transfusion, including meticulous surgical 
technique, controlled hypotension, regional anaesthesia, autologous blood transfusion, intra-
operative blood salvage, and the use of erythropoietin and antifibrinolytic agents [14]. During 
the previous decade several studies have proven the beneficial, blood loss reducing effect of 
perioperatively administered antifibrinolytic drugs in orthopaedic patients [15]. Amongst them, 
tranexamic acid has become a regular part of perioperative protocols in lower limb arthroplasty 
[16]. 
Minor bleeding complications related to the surgical wound and to the soft-tissue 
envelope around the surgical site and their effects on functional outcomes are as significant 
concerns for orthopaedic surgeons as major bleeding complications are. The wound haematoma 
following a joint replacement can potentially lead to a periprosthetic joint infection or to joint 
stiffness and a compromised functional outcome. These type of complications were neglected 
previously, however during the last few years they have received increased attention as 
potentially preventable complications. 
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Bleeding risk and possible contraindication to antithrombotic agents must be assessed 
before initiating thromboprophylaxis. Although potential risk of bleeding complications has not 
been traditionally addressed as a part of other guidelines, in 2011 the American Academy of 
Orthopaedic Surgeons’ (AAOS) work group stated the seriousness of these concerns during 
preparing the update for American College of Chest Physicians’ (ACCP) guidelines on VTE 
prophylaxis [17]. Bleeding complications and their consequences are a major concern for 
surgeons during chemoprophylaxis, and should be considered when deciding on the type and 
time of initiation of the therapy. Personalized risk stratification has become an important part 
of the new era of VTE prophylaxis to reduce all types of perioperative bleeding risks to the 
lowest possible level. 
 
2. Conceptual background 
2.1. The clotting cascade 
‘The clotting mechanism consists of self-regulating processes that result in the production 
of a fibrin thrombus. These processes are controlled by inactive cofactors that, when activated, 
promote or accelerate clotting (Figure 1). These processes usually occur on the surfaces of the 
platelets or macrophages, or in the endothelial cells, and are initiated by two specific pathways: 
extrinsic and intrinsic. The extrinsic pathway is initiated as a result of activation of tissue 
lipoproteins resulting from mechanical injuries such as trauma and/or surgery. The intrinsic 
pathway involves circulating plasma factors. Both pathways are found at the level of factor X, 
transformed into factor Xa. This factor promotes the conversion of prothrombin into thrombin 
(factor II), which in turn, transforms the fibrinogen into fibrin, this being the key step for the 
formation of the thrombus. The plasmin digests the fibrin, as well as inactivating the V and VIII 
factors and fibrinogen, restoring normal blood flow. There are three anticlotting mechanisms 
that prevent the formation of thrombi: antithrombin (AT), C and S proteins, and the extrinsic 
pathway inhibition (tissue factor). In case of surgery or trauma, there is a decrease in circulating 
AT level, which stimulates the clotting process. Studies have shown that this decrease in AT is 
greater, and remains for longer in THR than in cases of general surgery. In a previous study 
low AT levels were found in patients diagnosed with DVT after surgery [18]’. 
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Figure 1 The haemostatic equilibrium: fine balance between coagulation and fibrinolysis. In 
Hungary currently available anticoagulants and antifibrinolytics for patients undergoing THR 
also can be seen with their action of mechanism. More information in the text below. 
 
 
2.2. Hip replacement as a risk factor for VTE 
There have been many reported risk factors for VTE, these include age, obesity, varicose 
veins, family history of VTE, thrombophilias, combined oral contraceptives, hormone 
replacement therapy, anti-oestrogens, pregnancy, puerperium, immobilization, long-haul 
travel, hospitalization, anaesthesia and central venous catheters [19]. Practically every patient 
admitted to a hospital has at least one of the above mentioned risk factors. Hip replacement is 
a major orthopaedic intervention, meaning it is a strong risk factor for VTE. Because the risk 
factors are cumulative, any other associated condition belonging to the moderate or weak risk 




Table 1 Severity of risk factors for VTE 
 
A risk stratification of the risk for VTE classifies orthopaedic patients who have 
undergone hip or knee arthroplasty in the highest risk category [8]. Randomized clinical trials 
have concluded that the rates of venographically documented DVT and proximal DVT seven 
to fourteen days after major orthopaedic surgery in patients who did not receive any VTE 
prophylaxis are approximately 40% to 60% and 10% to 30%, respectively [19]. After discharge 
from hospital, these orthopaedic patients are still at risk for VTE. Hypercoagulability can 
persist, therefore VTE can occur up to three months [20] postoperatively and is the most 
common cause for readmission after THR [19]. 20% of THR patients with negative venogram 
at discharge and no VTE prophylaxis had a new DVT that developed over the subsequent three 
weeks based on repeated venogram [21]. With routine VTE prophylaxis in orthopaedic patients, 
fatal PE is uncommon, and the rates of symptomatic VTE within three months have been 
reduced to 1.3% to 10% [8, 19]. 
 
2.3. VTE prophylaxis 
DVT of the limbs is the development of a blood clot in one of the major deep veins in the 
extremities, which leads to impaired venous blood flow. It most frequently occurs in the lower 
limbs, causing leg swelling and pain. PE is a consequence of thrombus formation in the deep 
venous system of the lower extremities. The deep venous thrombi might embolize to the 
Risk factors for VTE: 
Strong Moderate Weak 
• fracture of the hip or leg • arthroscopic knee surgery • bed rest > 3 days 
• hip or knee replacement • central venous catheters • immobilization or bedridden 
• major general surgery • chemotherapy • advanced age 
• major trauma • congestive heart or respiratory failure • laparoscopic surgery 
• spinal cord injury (SCI) • hormone replacement therapy • obesity 
 • malignancy • pregnancy/antepartum 
 • oral contraceptive therapy • varicose veins 
 • paralytic stroke  
 • pregnancy/postpartum  
 • previous VTE  
 • thrombophilia  
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pulmonary vasculature, resulting in a PE. VTE prophylaxis consists of mechanical and 
pharmacologic measures to reduce the risk of deep vein thrombosis and pulmonary embolism. 
 
2.4. Guidelines on VTE prophylaxis after orthopaedic interventions 
The most frequently cited international guidelines recommending anticoagulation for 
patient undergoing hip arthroplasty are: 
1) American College of Chest Physicians (ACCP): “Prevention of Venous 
Thromboembolism in Orthopaedic Surgery Patients: Antithrombotic Therapy and Prevention 
of Thrombosis” (9th edition, published in 2012) [7]. In 2016, the ACCP updated 
recommendations on 12 topics that were in the 9th edition of their guidelines, and addressed 
three new topics. However these did not change the recommendations regarding orthopaedic 
patients [22]. 
2) American Academy of Orthopaedic Surgeons (AAOS): “Clinical Practice Guideline 
on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee 
Arthroplasty” (published in 2012) [23]. 
3) Scottish Intercollegiate Guidelines Network (SIGN): “Prevention and management of 
venous thromboembolism” (published in 2010, updated in 2015) [11]. 
4) British National Institute for Health and Care Excellence (NICE): “Venous 
thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or 
pulmonary embolism” (published in 2018, updated in 2019) [24]. 
5) The last available Hungarian guideline on VTE prophylaxis is ’Reduction and 
treatment of thromboembolism’ (published in February 2010, and was valid until 31st December 
2013, has not been updated). It contains the recommendation on thromboprophylaxis for 
patients after THR [25]. 
 
2.5. Mechanical VTE prophylaxis 
The mechanical methods for VTE prophylaxis include early mobilization, graduated 
compression stockings, intermittent pneumatic compression device and venous foot pumps 
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[24]. Advantages of mechanical VTE prophylaxis include the lack of bleeding potential, no 
need for laboratory monitoring and no clinically important side effects [19, 24]. Furthermore, 
the effectiveness of anticoagulants may be enhanced by some mechanical methods. 
Disadvantages of mechanical VTE prophylaxis methods include the difficulty of 
implementation and compliance issues due to the limited movement of the patient and the 
discomfort they may bring [18], needing to be worn continuously pre-, intra- and post-
operatively for 72 hours. There is also a lack of strong evidence that any of the mechanical VTE 
prophylaxis methods can reduce the risk of death or PE. There are also frequent 
contraindications to their use (fragile 'tissue paper' skin, venous leg ulcers, suspected or proven 
peripheral arterial disease, etc.) [24]. 
Early mobilization is probably the most simple and easily applicable method of VTE 
prophylaxis [18]. Early walking has been associated with a lower incidence of post-THR 
symptomatic VTE. It must be noted that although the early and frequent ambulation of 
hospitalized patients at risk for VTE is an important principle of patient care, the majority of 
hospital-associated, symptomatic VTE events occur after the patients have started to ambulate 
[26]. Therefore, mobilization alone does not provide adequate VTE prophylaxis for hospitalized 
patients and should be regarded with caution [19]. 
The latest available guidelines from the ACCP (2012) suggest the use of mechanical 
methods in addition to pharmacological prophylaxis during hospitalization in patients with high 
risk for VTE after major orthopaedic surgery. In particular, the use of ICPDs with portable 
batteries is recommended in order to achieve maximum compliance [7]. SIGN (2010) and 
Hungarian (2010) guidelines both mention mechanical methods as an additional way to 
complement pharmacological prophylaxis for VTE prevention [11, 25]. 
 
2.6. Pharmacologic VTE prophylaxis for THR according to current guidelines 
The current guidelines recommend the use of pharmacologic VTE prophylaxis for 28-35 




2.6.1. Acetylsalicylic acid 
Acetylsalicylic acid is a widely used, inexpensive, orally administered medication which 
is controversial as a solo thromboprophylactic agent. It irreversibly inhibits the COX-1 enzyme, 
preventing the formation of thromboxane A2, which is an important cofactor for thrombocyte 
activation and aggregation. Acetylsalicylic acid is suspected to downregulate tissue factor 
expression, thrombin formation, and reduce thrombin-mediated coagulant reactions [8]. 
The 8th ACCP guidelines in 2008 clearly recommended against the use of aspirin alone 
as VTE prophylaxis for any patient group including orthopaedic patients [19]. In contrast to 
this, the 9th ACCP guidelines in 2012, after accepting the suggestions of the AAOS, do 
recommend the use of acetylsalicylic acid as VTE prophylaxis for patients undergoing THR, 
however the same guideline recommends the use of LMWH in preference to other agents 
including acetylsalicylic acid [7]. 
The SIGN guidelines in 2010 gave straightforward advice for physicians about the use of 
acetylsalicylic acid. It is not recommended as the sole pharmacological agent for VTE 
prophylaxis in orthopaedic patients, because other agents are more effective for prevention of 
VTE [11]. 
In Hungary, the last available guideline gave clear recommendation against the use of 
acetylsalicylic acid as VTE prophylaxis in patient after THR [25]. 
Generally, the use of aspirin as a VTE prophylactic agent in orthopaedic patients remains 
controversial, because of the limited quality of the available evidence. According to recently 
published meta-analyses and review papers, aspirin seems to be a suitable drug for prevention 
of VTE after THR in low risk patients, however further well-designed randomised controlled 
trials are needed for the correct dosage and duration of administration of aspirin [28, 29]. 
 
2.6.2. Vitamin K antagonists 
Vitamin K antagonists (VKAs) were the first classic oral anticoagulants. VKAs impair 
the biosynthesis of functional vitamin K–dependent proteins by the competitive inhibition of 
vitamin K epoxide reductase. This action limits the production of carboxylated vitamin K–
dependent coagulation factors II, VII, IX, and X, as well as coagulation regulatory factors 
protein C and protein S. VKAs have a narrow therapeutic window, and determination of their 
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therapeutic dose in clinical practice is challenging. Adverse events, such as bleeding, frequently 
occurred among individuals initiating therapy [30]. A therapeutic INR (international 
normalized ratio) range of 2.0 to 3.0 with a target INR of 2.5 is recommended rather than a 
lower or higher range, therefore monitoring of the INR and dosage adjustment are always 
required. When warfarin is administered, an initial effect on INR usually occurs within the first 
two to three days. Consequently, when a rapid anticoagulant effect is required, heparin or 
LMWH should be administered concurrently. This administration should be overlapped for at 
least two days with warfarin until INR reaches the therapeutic range to allow for further 
reduction of factors X and II [8, 31]. 
VKAs are recommended by the latest ACCP guidelines for VTE prophylaxis in patients 
undergoing THR [7]. VKAs are not mentioned in the NICE and SIGN guidelines as an optional 
thromboprophylactic method for elective THR [11, 24]. The last available Hungarian guideline 
in 2010 gave clear recommendation against the use of VKAs as VTE prophylaxis in patient 
after THR [25]. 
 
2.6.3. Unfractionated heparin 
Unfractionated heparin (UFH) is a heterogeneous mixture of glycosaminoglycans that 
binds to AT via a unique pentasaccharide sequence and catalyses the inactivation of thrombin, 
factor Xa and other clotting enzymes [32]. The heparin-AT complex inactivates thrombin 
(factor IIa) and factors Xa, IXa, XIa and XIIa. Heparin must be administrated parenterally. The 
two preferred administration routes are continuous intravenous (IV) infusion and subcutaneous 
[8]. The use of UFH may lead to haemorrhagic complications. Because anticoagulant response 
varies among patients, monitoring UFH with tests and adjusting the dose is standard practice. 
The anticoagulant effect of UFH is usually monitored using the activated partial thromboplastin 
time (aPTT). The anticoagulant effects of the UFH can rapidly be reversed with the use of IV 
protamine sulphate [32]. UFH may also lead to non-haemorrhagic side effects, such as heparin-
induced thrombocytopenia (HIT) and osteoporosis, because it also inhibits osteoblast formation 
and activates osteoclasts promoting bone loss [8, 33]. HIT is an immune mediated adverse drug 
reaction caused by the emergence of antibodies that activate platelets in the presence of heparin. 
Despite thrombocytopenia, the bleeding complications are rare. HIT tends to cause 
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hypercoagulable condition associated with thromboembolic complications involving both the 
arterial and venous systems [34]. 
UFH is recommended by the latest ACCP guidelines for VTE prophylaxis in patients 
undergoing THR [7]. UFH is not mentioned in the NICE and SIGN guidelines as an optional 
thromboprophylactic method for elective THR [11, 24]. The last available Hungarian guideline 
in 2010 gave clear recommendation against the use of UFH as VTE prophylaxis in patient after 
THR [25]. 
 
2.6.4. Low molecular weight heparins 
Low molecular weight heparins (LMWHs) are derived from UFH by chemical or 
enzymatic depolymerization. Their molecular weight is approximately one-third that of UFH. 
LMWHs have a more favourable benefit-to-risk ratio with superior pharmacokinetic properties 
compared with UFH. The inhibitory activity of LMWHs against factor Xa is greater than 
thrombin and exhibits less binding to cells and proteins (Figure 1), consequently, LMWH 
preparations have more predictable pharmacokinetic and pharmacodynamic properties, a longer 
half-life and a lower risk of non-haemorrhagic side effects than UFH. They are administered 
daily in one or two doses depending on the required dose and current guidelines. LMWHs are 
subcutaneous injections without the need of monitoring. An uncommon but potentially 
devastating complication of LMWHs is HIT syndrome. The risk for HIT is much less than what 
has been reported with UFH (0.2% vs. 2.6%) [35]. In summary, the use of LMWHs are more 
convenient than UFH, therefore they have replaced UFH for almost all clinical indications [8, 
32]. 
Over the last 20 years, many studies reported the superiority of LMWH over the 
previously mentioned anticoagulants [19, 27, 36-38]. In patients undergoing orthopaedic 
interventions LMWHs are more efficacious than aspirin or either adjusted-dose UFH or 
warfarin, when used for the prevention of DVT and their administration also results in 
significantly less minor bleeding complications when compared with UFH, but significantly 
more minor bleeding when compared to warfarin and aspirin [19, 27, 37]. LMWHs have 
become standard thromboprophylactic drugs amongst orthopaedic patients [36]. Enoxaparin, is 
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one of the most favoured subcutaneously administered antithrombotic agent in Europe, and was 
used as the comparator during clinical trials with the direct oral anticoagulants (DOACs). 
The latest ACCP guidelines recommended LMWH as the optimal method for VTE 
prophylaxis in patients undergoing THR [7]. The NICE and SIGN guidelines and also the last 
available Hungarian guidelines on VTE prophylaxis gave recommendation for the use of 
LMWH in preference to other agents as alternatives for VTE prophylaxis in patient after THR 
[7, 11, 25]. Recent NICE guidelines suggest LMWH for 10 days and then aspirin for another 
28 days or LMWH for 28 days in combination with anti-embolism stockings until discharge for 
patients undergoing elective THR [24]. LMWH should be considered the gold standard for VTE 
prophylaxis in orthopaedic patients. 
 
2.6.5. Fondaparinux 
Fondaparinux is a synthetic pentasaccharide with specific anti-Xa activity. 
Pharmacologically, fondaparinux binds to AT and produces a conformational change at the 
reactive site of AT that enhances its reactivity with factor Xa (Figure 1). The daily dose of 
fondaparinux is 2.5 mg subcutaneously for VTE prophylaxis [32]. A benefit of fondaparinux 
over other injectable agents such as UFH and LMWH is that it does not inactivate thrombin, 
has no effect on platelets and does not cause HIT [8, 18]. 
The latest ACCP guidelines recommend fondaparinux as a method of VTE prophylaxis 
for patients undergoing THR [7]. However, the same guidelines report that the close balance 
between advantages and disadvantages of fondaparinux makes its use less appealing than 
LMWH for extended VTE prophylaxis [7]. SIGN and Hungarian guidelines mention 
fondaparinux as an alternative method for VTE prophylaxis [11, 25]. The recent NICE 
guidelines do not mention fondaparinux for patient undergoing elective THR, however in case 
of hip fractures it is still a recommended method [24]. In Hungary fondaparinux is still 
available, however the national health insurance does not support its prescription for 
orthopaedic patients undergoing any elective arthroplasty. 
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2.6.6. Direct oral anticoagulants 
Compared with VKAs, the new direct oral anticoagulants (DOACs) [39] have the 
advantage of administering them at fixed doses without the need of laboratory monitoring. 
Subsequently, they have the potential to overcome several drawbacks of VKAs [7, 8]. There 
are several commercially available DOACs that are licensed for thromboprophylaxis.  
 
2.6.6.1. Apixaban 
Apixaban is an oral direct inhibitor of factor Xa that has been approved for VTE 
prophylaxis following THR (Figure 1). There are studies that compared the efficacy of apixaban 
versus enoxaparin that led to the approval of apixaban for VTE prophylaxis after major 
orthopaedic interventions [40, 41] The current recommended dosage for VTE prophylaxis after 
THR is 2.5 mg twice daily starting 12 to 24 hours after surgery and continuing for 35 days for 
THR [8, 42]. Apixaban is also recommended by the latest NICE and ACCP guidelines as 
options for the prevention of venous thromboembolism in adults undergoing elective THR [7, 
24]. The latest SIGN and Hungarian guidelines on thromboprophylaxis were released in 2010. 
Apixaban, a year later received its European marketing authorization for VTE prophylaxis in 
patients undergoing elective THR, therefore apixaban was not even mentioned in these 
guidelines [11, 25]. Despite this, apixaban is available in Hungary and national health insurance 
recommends its prescription and its use for patients undergoing elective arthroplasty [43]. 
 
2.6.6.2. Edoxaban 
Edoxaban is a novel, orally administered direct inhibitor of factor Xa. Edoxaban 15 mg 
and 30 mg tablets were approved for prevention of deep vein thrombosis in patients undergoing 
elective arthroplasty in 2011 in Japan. The use of edoxaban is authorized in Europe to treat and 
prevent DVT and PE from re-occurring, to prevent stroke and systemic embolism in patients 
with non-valvular atrial fibrillation. It also should be noted that edoxaban is only approved for 
VTE prophylaxis in Japan. It has not yet approved for this indication in Europe and the United 




Rivaroxaban is also an orally administered direct factor Xa inhibitor (Figure 1). In 2008, 
rivaroxaban received marketing authorization for VTE prophylaxis in adult patients undergoing 
elective THR [46]. It was found to be more effective than enoxaparin in preventing VTE after 
THR [47, 48]. Rivaroxaban is administered for VTE prophylaxis after elective THR and TKR 
in a fixed daily oral dose of 10 mg started 6-10 hours after surgery once haemostasis has been 
established [8, 46]. The latest ACCP guidelines recommend rivaroxaban as a method of VTE 
prophylaxis in patients undergoing THR [7]. Rivaroxaban is also recommended by the latest 
NICE, SIGN and Hungarian guidelines as an option for the prevention of VTE in adults 
undergoing elective THR [11, 24, 25]. 
 
2.6.6.4. Dabigatran etexilate 
Dabigatran is a selective, reversible, direct thrombin (factor II) inhibitor (Figure 1). It is 
administered as dabigatran etexilate, which is an orally absorbable prodrug, since dabigatran 
itself is a strongly polar molecule that is not absorbed from the gut. Phase III clinical studies 
evaluated the use of dabigatran etexilate for VTE prophylaxis after elective THR and it has 
been approved in many countries. Its efficacy was analysed in studies that compared dabigatran 
etexilate (220 or 150 mg per day) with enoxaparin in patients undergoing THR [49-52]. Studies 
reported that dabigatran etexilate was as effective as enoxaparin for VTE prophylaxis. For VTE 
prophylaxis, the dosing regimen of dabigatran is 150 mg or 220 mg daily, starting with a half 
dose 1-4 hours after surgery [24, 25]. In 2012, Uchino et al [53] reported that there is an 
association between dabigatran and an increased risk of myocardial infarction or acute coronary 
syndrome in a number of patients when tested against different controls [8]. Despite these 
findings, the latest ACCP, SIGN and Hungarian guidelines recommend dabigatran as a method 
of VTE prophylaxis in patients undergoing THR [7, 11, 25]. The latest NICE guideline is more 
conservative, because it suggests that dabigatran should only be used as a second line drug for 




Antifibrinolytics are tranexamic acid (TXA), aprotinin and ɛ-aminocaproic acid. They 
utilize different mechanisms to inhibit the dissolution of blood clots. A number of studies have 
investigated their efficacy during perioperative period in THR [54, 55]. TXA is cheaper and 
safer than aprotinin and approximately ten times more potent and less toxic than ɛ-aminocaproic 
acid with overall good penetration into joints [56, 57]. The use of TXA has gained significant 
popularity during major orthopaedic interventions [54].  
 
2.7.1. Tranexamic acid 
TXA is a synthetic antifibrinolytic agent, which competitively inhibits the conversion of 
plasminogen to plasmin, preventing fibrin degradation and preserving the stable framework of 
fibrin's matrix structure. During the last decade TXA has become a regular part of perioperative 
protocols in lower limb arthroplasty by the virtue of reducing perioperative blood loss and 
lowering transfusion rates. In the United Kingdom, TXA is recommended for all surgery where 
blood loss is expected to be greater than 500 ml [58]. TXA is not approved by the Food and 
Drug Administration for this purpose in the United States. In Hungary, slow intravenous 
administration of daily 500-1000 mg TXA (divided into two or three doses) was authorized for 
prophylaxis of local fibrinolysis [59, 60]. 
Most of the studies have been carried out in orthopaedic surgery, where tranexamic acid 
has been shown to reduce the rate of allogeneic blood transfusion by up to 69% [15] after hip 
and knee surgery, without the increased risk of complications, including thromboembolic 
events [55, 61]. Whilst its effectiveness and safety have been examined by several studies [54, 
62], the route, timing and dosage of TXA using in THR is still controversial [63]. It can be 
applied orally, directly to the surgical site or through intravenous administration starting pre-, 
intra- or postoperatively [16, 64-67]. 
Absolute contraindications to the administration of TXA include known allergy to TXA, 
known defective colour vision, greater than 3 hours after traumatic injury, pre-existing active 
thromboembolic disorder, disseminated intravascular coagulation or fibrinolytic conditions 
following consumptive coagulopathy, acute renal failure, coronary or vascular stents placed 
within the last twelve months and acute subarachnoid haemorrhage. Relative contraindications 
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might include known epilepsy, renal dysfunction, high risk of venous or arterial thrombosis, or 




The data from development trials suggests that the thromboprophylactic efficacies of the 
new DOACs are at least equivalent or potentially superior to the clinical trial comparator 
LMWH, enoxaparin. However, these new agents might be associated with a potentially higher 
bleeding tendency [36, 47, 49-51, 70, 71]. Several reviews and trials warned of a potentially 
higher postoperative bleeding and wound infection rate of DOACs [72, 73]. Our clinical 
experiences with elevated serous wound discharge enticed us to design a prospective study 
based on our everyday experience and explore the bleeding profile of DOACs focusing on 
minor bleeding. The number and severity of minor bleeding and wound complications were 
neglected during the dose-finding and dose-ranging clinical trials. Orthopaedic surgeons 
encounter these problems frequently, and indirectly the number of these complications 
determine the adherence to international and national VTE prophylaxis guidelines. Clinical 
trials with dabigatran etexilate for THR focused on major and clinically significant bleeding 
complications, as safety endpoints, with little attention paid to surgically relevant outcomes, 
such as wound healing, drainage, and surgical site infection [49-51]. 
1. In Study I our aim was to compare the safety profile of enoxaparin and dabigatran 
etexilate in the use of primary THR, with particular attention to minor haemorrhagic and 
soft tissue adverse effects during the early postoperative period. 
 
Most of the studies describing the perioperative major bleeding complication and blood 
loss reduction effect of TXA, used LMWHs for VTE prophylaxis. Only a very few studies are 
known to examine TXA’s beneficial effect when the new DOACs are used as perioperative 
anticoagulants in patients undergoing cemented THR [74, 75]. Studies with TXA also neglected 
to explore its effect on minor bleeding and wound complications. 
2. In Study II our aim was to prospectively assess the efficacy of tranexamic acid on 
postoperative blood loss when rivaroxaban is used as thromboprophylaxis after 
cemented THR. In addition, we examined whether TXA has any effect on minor 
bleeding complication.  
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4. Materials and methods 
Routine preoperative assessment included laboratory tests, such as renal and liver 
function tests, aPTT, prothrombin time (PT) and INR. Patients were excluded if they had had 
renal and/or hepatic dysfunction, a history of coagulopathy, previous thromboembolic event, 
previous cardiovascular implants or bypass surgery, prolonged anticoagulant therapy or 
extended antiplatelet drug intake (acenocoumarol, warfarin, clopidogrel, acetylsalicylic acid 
more than 100 milligrams), known epilepsy or allergy to tranexamic acid or to the administered 
anticoagulant. If patients underwent revision surgery were also excluded from the study. 
Non-steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid ≤100 mg were 
suspended one week prior to surgery in all patients. 
Operations were performed under either general, regional or combined general and 
regional anaesthesia, depending on the anaesthetic team’s decision. All operations were 
performed by seven consultant orthopaedic surgeons working in a single orthopaedic 
department, using a direct lateral or Bauer’s approach. All operations were performed without 
utilizing a cell saver or other retransfusion systems. Cefuroxime or clindamycin (in case of 
confirmed allergy to penicillin) were used as perioperative antibiotic prophylaxis. The 
intraoperative blood loss was recorded from the contents of the suction canister in the operating 
theatre. At the beginning of the observational study period (Study I), according to our 
institutional protocol, two closed suction drains were used for 24hrs postoperatively. After 
analysing the results of the initial period we decided to introduce blood conservation techniques 
to reduce our blood transfusion rate. Therefore during the second part of our observational study 
(Study II) only one intra-articular drain was used for a maximum of 24 hours. To quantify the 
volume of drainage, it was collected in calibrated and scaled bottles. The wound and drain sites 
were covered with the same sized Mepore® bandages after drain removal. 
In terms of pain relief, paracetamol, tramadol and metamizole were administered as 
required. Physiotherapy was started on the first postoperative day with fully weight bearing on 
the operated lower limb, with restriction of adduction and external rotation. 
During the observational study period the effect of the newly introduced medications 
(anticoagulants and antifibrinolytics) on thrombotic and bleeding complications were examined 
at our Department. Namely, the minor bleeding events and the major and clinically significant 
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bleedings were recorded according to previous publications and guidelines [49, 76]. Our main 
focus was on perioperative blood loss and minor bleeding events, therefore more detailed 
information were collected in these topics such as bleeding and oozing through the surgical 
wound, area of skin haematoma and perioperative change in thigh volume. 
 
4.1. Thrombosis and thromboembolism 
Thromboembolic events were recorded when clinical signs emerged. In case of a 
suspected DVT (swelling, excessive oedema, discoloration of the limb or a positive Mayer’s or 
Homans’ sign) colour duplex sonography of the affected limb was performed. Clinical 
suspicion of PE meant an urgent need for computed tomography with pulmonary angiography 
according to our protocol.  
During the first period, in Study I, 3 months after the intervention all of the patients were 
phoned and asked whether they had been diagnosed or treated with DVT or PE. 
Later, during the second period, in Study II, the postoperative venous events were not 
routinely screened, but all clinically relevant events up to a minimum of 6 weeks after the 
operation were recorded. 
 
4.2. Major and clinically significant bleeding events 
Major bleeding was defined as fatal bleeding; overt bleeding associated with ≥ 20 g/L fall 
in Hb; overt bleeding leading to transfusion of ≥ 2 units packed cells or whole blood; 
retroperitoneal, intracranial, intraocular or intraspinal bleeding; bleeding warranting treatment 
cessation or leading to reoperation.  
Clinically significant bleeding events were defined as spontaneous skin haematoma 
≥ 25 cm2, wound haematoma ≥ 100 cm2, spontaneous nose or gingival bleeding > 5 min, 
spontaneous or intervention associated macroscopic haematuria lasting > 24 h, and any other 
bleeding event considered clinically significant [49-51].  
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4.3. Minor bleeding events 
Minor bleeding was defined as wound bleeding, serous wound discharge classified in four 
categories and wound haematoma smaller than 100 cm2 (Table 2 and 3). 
 
4.4. Bleeding through the surgical incision and serous wound discharge 
Definition of wound bleeding was the bleeding from the surgical wound into the dressing 
during the first postoperative 24 hours, until drain removal. Its intensity was categorized 
according to Table 2. 
Serous wound discharge was defined as the oozing of the surgical wound and drain site 
after drain removal. The duration of discharge was examined every day, its cessation was 
precisely documented. The intensity of serous wound discharge was observed as well. On the 
3rd and 7th postoperative days its exact amount was documented according to the previously 
established categories (Table 2), when wound dressings were checked over the surgical incision 
and the drain site. Subgroup analysis was performed for the patients who were last on the 
operating list each day, because in these cases the earlier anticoagulation administration (shorter 
period between the wound closure and next dose of thromboprophylaxis) might cause increased 
amount of wound bleeding and prolonged discharge. 
 
Table 2 Categories of wound bleeding (postoperative 0-24 h) and serous wound discharge 
(after drain removal): 
0 Clean and dry wound dressing 
1 Small spots but not wet through 
2 A part of the wound dressing wet through during a day 
3 The dressing wet through fully during a day, change and/or covering gauze were 
necessary 
 
4.5. Skin haematoma 
The area of skin haematoma (suffusion) was measured and patients were categorized 
according to our previously established criteria (Table 3, Figure 2). 
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Table 3 Categories of haematoma: 
 
0  none 
1  <100 cm2 
2  100-200 cm2 
3  200-300 cm2 
4  300-400 cm2 
5  400-500 cm2 
6  500 cm2< 
 
4.6. Change in thigh volume 
Excessive oozing might be associated with increased thigh volume after THR [77]. Jones 
and Pearson’s anthropometric method objectively estimates leg volume by partitioning the leg 
into six segments which are similar to truncated cones [78]. The upper three of these segments 
were used to calculate the thigh volume (Figure 
3). The measurements were carried out with the 
patient standing erect and the feet slightly apart. 
Four circumferences were taken with a metric 
tape at predetermined sites: 1) the gluteal furrow, 
2) one-third of the subischial height up from the 
knee joint line, 3) the minimum circumference 
above the knee, 4) the maximum circumference 
around the knee. For each circumference, the 
heights above the floor level were measured by 
a stadiometer. Thigh volume (mL) was 
calculated by summing up the volumes of the 
three truncated cones. Thigh volumes were 
measured preoperatively and on the 7th 
postoperative day. 
Figure 2 Example for skin haematoma 
after THR from 6th category 
Figure 3 Measurement sites of 
circumferences for thigh volume 
calculation [78].  
Explanation is in the text. 
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4.7. Calculation of total perioperative blood loss 
Study I: The calculated perioperative blood loss (V, mL) was compared between the two 
groups. For this purpose, the patient’s height (H, cm), weight (G, kg) and haematocrit level 
preoperatively (Hct0) and on the first postoperative day (Hct1) were recorded. Patients, who got 
transfusion in the first 24 h after the operation, were excluded from this calculation. Nadler’s 
formula was used for calculating the perioperative blood loss [79]: 
V = EBV x ln(Hct0/Hct1) 
Estimated blood volumes (EBV) were calculated with the following formula: 
EBV = A x H0,725 x G0,425 - B 
where A = 0.0236 for men; A = 0.0248 for women; B = 1.229 for men; B = 1.954 for 
women. 
 
Study II: During Study II, when the blood loss reducing effect of TXA was examined, a 
different calculation was used, which took into account postoperative haemodilution and 
transfusion requirement as well. The Hb and Hct levels were measured on the first, second and 
fifth day after the operation. The blood volume and haemodilution were assumed to normalize 
on the fifth day. The total perioperative blood loss was monitored as total drop in Hct level on 
postoperative fifth day compared to the preoperative Hct level. The patient’s blood volume 
(PBV) was calculated using the Nadler’s formula [79] as follows: 
PBV (litres) = (k1 x height3 (m)) + (k2 x weight (kg)) + k3, 
where k1= 0.3669, k2 = 0.03219 and k3 = 0.6041 for men, and k1 = 0.3561, k2 = 0.03308 
and k3 = 0.1833 for women. 
Multiplying the PBV by the haematocrit (Hct), gives the red blood cell (RBC) volume. 
Thus a change in the RBC volume can calculated from a change in the Hct level [80] as follows: 
Total RBC volume loss = PBV x (Hctpre-op – Hctpost-op) 
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The number of units of blood transfused during the hospital stay was recorded. 
Transfusion (mean volume per unit: 280 mL, mean Hct per unit: 0.55) were taken into account 
by calculating the total blood loss as follows: 
Total blood loss (litres) = (Total RBC volume loss + (Number of units transfused x 0.28 x 
0.55)) / ((Hctpre-op + Hctpost-op) / 2) 
 
4.8. Treatment protocols 
Study I: We prospectively collected and reviewed all patients undergoing primary 
cemented THR for osteoarthritis or avascular necrosis of the femoral head from February 2011 
until March 2012. These patients were divided into two groups to receive either LMWH 
enoxaparin (Clexane®, Sanofi-Aventis) or the oral direct thrombin inhibitor dabigatran 
etexilate (Pradaxa®, Boehringer Ingelheim International). Patients were enrolled in each group 
according to our weekly altered medication supply: every odd week enoxaparin and every even 
week dabigatran was administered. Our study thus can be called a quasi randomised study. 
Anticoagulants were administered according to the current orthopaedic and manufacturer 
guidelines [11, 19, 27, 81]. In the enoxaparin group, 40 mg enoxaparin was given 
subcutaneously 12 hours before operation and at 8 pm for the next 28-35 days postoperatively. 
In the dabigatran group, dabigatran etexilate 220 mg was administered for patients below 
75 years of age and 150 mg for patients over 75 years of age. Administration was started 
4 hours postoperatively with a half-dose (110 mg or 75 mg) and then the full dose was 
administered once a day at 8 am for 28-35 days after replacement [7, 11, 81, 82]. 
 
Study II: Tranexamic acid was introduced in our Department at the end of 2013, after 
successful trials in both elective and trauma surgery, as a perioperative potentially blood-
conserving adjunct during primary lower limb arthroplasty. Consecutive patients undergoing 
primary cemented THR were studied prospectively. Patients received TXA perioperatively 
between January 2014 and November 2014 designated as TXA group. We compared this data 
to a group of patients who underwent the same procedure, between February 2012 and 
December 2012 (control group), before the introduction of TXA. All patient data in each 
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observational period was prospectively collected, reviewed and all patients received a primary 
cemented THR for osteoarthritis or avascular necrosis of the femoral head. In both groups 10 
mg rivaroxaban (Xarelto®, Bayer Schering Pharma) was administered as perioperative 
thromboprophylaxis, started 6 hours postoperatively, then once a day at 8 pm for 28-35 days 
after joint replacement surgery according to the current orthopaedic and manufacturer 
guidelines [7, 11, 24]. 
 
4.9. Statistical analysis 
In Study I, the statistical analysis was done using t-test, chi-square test and ANOVA with 
StatSoft® Statistica v.9 statistical software. 
In Study II SPSS Statistics 16.0 software was used for statistical analysis. Normal 
distribution of the data was analysed by the Shapiro-Wilk test. Parametric (Student’s T-test) 
and non-parametric (Mann-Whitney U-test) tests were used for the comparative analyses of 
data with normal and non-normal distribution, respectively. Categorical variables were 
analysed by the Chi-square method, with the use of Fischer’s exact test, when appropriate. 
Results and data are presented in the text as mean (± standard deviation (SD)) or median 
(interquartile range). The p-values below 0.05 were regarded as statistically significant. 
 
4.10. Ethical approval 






Study I:  
122 patients were enrolled, 61 into each group. The number and descriptive data of the 
patients are presented in Table 4. Characteristics of patients were similar, without no significant 
differences. 
 
Table 4 Patient characteristics ± SD (min-max) 
 Enoxaparin Dabigatran 
Number of patients 61 61 
Gender 16♂/45♀ 17♂/44♀ 
Average age 69 ± 9.7 (47-85) 69 ± 7.6 (52-86) 
Height (cm) 164 ± 8.9 (150-189) 164 ± 8.0 (148-186) 
Weight (kg) 77 ± 14.1 (45-100) 76 ± 11.6 (48-99) 
BMI (kg/m2) 28.5 ± 4.8 (19.1-37.7) 28.3 ± 4.3 (17.9-40.9) 
Estimated blood volume (mL) 4464 ± 743.8 (2775-6241) 4458 ± 637.9 (2859-5893) 
Haematocrit before surgery 0.40 ± 0.038 (0.30-0.50) 0.40 ± 0.038 (0.31-0.50) 
Haemoglobin before surgery (g/L) 134.7 ± 15.7 (94-176) 135.9 ± 13.5 (101-172) 





No patients developed clinical features of DVT during the treatment and follow-up 
period, therefore duplex sonography was not performed. No PE events or deaths occurred 
during the hospitalization and within 3 months after the operation. 
There were no significant differences between the two groups in major bleeding events 
(Table 5). 22 patients in the dabigatran group and 21 patients in the enoxaparin group needed 
transfusion in the postoperative period. 
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Table 5 Significant bleeding complication in our study according to guidelines of previous 





Clinically overt bleeding leading to transfusion of 
≥ 2 units packed cells 
4 (6.6) 5(8.2) 
Wound haematoma ≥ 100 cm2 29 (47.5) 33 (54.1) 
Intervention associated macroscopic haematuria 
lasting > 24 h 
0 (0.0) 1 (1.6) 
 
No significant differences were found between the two groups in volume of blood loss 
during surgery: 300 ml (±137.23) in dabigatran group and 314 ml (±197.32) in the enoxaparin 
group was measured. Volume of the postoperative drainage also did not differ significantly: 
470.82 ml (±276.85) in dabigatran group and 471.64 ml (±253.3) in enoxaparin group was 
found. There were no significant differences in perioperative calculated blood loss, which were 
1072.4 ml (±586.6) in the dabigatran group and 1152.3 ml (±486) in the enoxaparin group. 
Subgroup analysis did not show any significant differences in wound bleeding/discharging and 
drainage volume regarding to patient’s position on the operating schedule (first or last on the 
list). No significant differences were found in the total blood loss as calculated by a total drop 
in preoperative and postoperative first day Hb level: 30.7 g/L (±13.5) using dabigatran and 28.3 
g/L (±12.7) using enoxaparin. 8 patients from the enoxaparin group and 3 patients from the 
dabigatran group received transfusion in the first 24 h after their operations, therefore they were 
excluded from this calculation and comparison of postoperative Hb drops. 
Wound bleeding also did not show significant differences between the two groups (Table 
6). 
 
Table 6 Wound bleeding incidences in the two groups. Data are shown as number of events, 
percentage in brackets (%). Definitions of categories are found in Table 2. 
Category: 0 1 2 3 


















Data on haematoma frequency is presented in Table 7. There was no statistical 
significance between groups.  
 
Table 7 Haematoma frequency. Data are shown as number of events, percentage in brackets 
(%). Definitions of categories are found in Table 3. 
































Significant increases of thigh volumes were observed in both groups on the 7th 
postoperative day compared to preoperative volumes, however, no significant difference was 
found between the two groups (Figure 4). 
 
Figure 4 Postoperative thigh volume increase. A significant increase (#) of thigh volume on 
the 7th postoperative day were found in both groups compared to preoperative volumes, 




In contrast to these, the main differences between the two groups are in the duration and 
intensity of serous wound discharge. Duration of wound discharge was 2.2 (±2.7) days in the 
dabigatran group and 1.2 (±1.9) days in the enoxaparin group after drain removal (p<0.05) 
(Figure 5). Significantly higher intensity of wound draining was found in the dabigatran group 
(p<0.05) (Table 8 and Figure 6). 
 
Figure 5 Duration of drain wound oozing in days. * means significant difference between the 
two groups (p<0.05). Duration of serous wound discharge was 2.2 (±2.7) days in the 
dabigatran group and 1.2 (±1.9) days in the enoxaparin group. 
 
 
Table 8 Number of patients with different categories of serous wound discharge. Data are 
shown as number of events, percentage in brackets (%). Definitions of categories are found in 
Table 2. 
 Day 3 Day 7 
Category: All 1 2 3  All 1 2 3 
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Figure 6 Intensity of serous wound discharge. (*) Significantly higher serous wound discharge 
was found in the dabigatran group on the 3rd and 7th postoperative days. (#) Significant 






81 patients were enrolled into the TXA group, who met our inclusion criteria and got 
perioperative tranexamic acid. They were compared with 87 patients in the control group. Our 
study population’s basic demographic, laboratory and surgical data is presented in Table 9. The 
two groups were statistically identical in terms of patient characteristics. 
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Table 9 Patient characteristics ± SD (min-max) 
 TXA group Control group 
Number of patients 81 87 
Gender 18♂/63♀ 21♂/66♀ 
Average age 68 ± 6.7 (46-81) 69 ± 8.2 (49-85) 
Height (cm) 163 ± 9.1 (140-195) 163 ± 7.9 (148-180) 
Weight (kg) 76.2 ± 12.4 (45-100) 74.5 ± 11.5 (54-100) 
BMI (kg/m2) 28.5 ± 3.8 (19.9-36.4) 28 ± 3.7 (21.6-38.5) 
Preoperative thigh volume (mL) 5194 ± 1129 (3153-7588) 4868 ± 1002 (2882-8210) 
Patients’ blood volume (L) 4.411 ± 0.711 (2540-6210) 4.353 ± 0.660 (3260-5800) 
Haematocrit before surgery 0.40 ± 0.038 (0.30-0.50) 0.41 ± 0.040 (0.30-0.48) 





Three patients in the control group developed clinical features of DVT during their 
hospital stay, however, colour duplex sonography did not prove our clinical suspicion. No VTE 
events or deaths were recorded during the study and within the investigated postoperative six 
week period. 
There was no difference in intraoperative blood loss between the two groups: 306.4 mL 
(±126.6 mL) in the TXA group and 316.7 mL (±170.5 mL) in the control group (p=0.957); 
however, the postoperative drainage differed significantly: 280 mL (170-350 mL) in the TXA 
group and 400 mL (300-550 mL) in the control group (p<0.001). The median calculated 
perioperative blood loss was significantly lower in the TXA group compared to the control 
group (p<0.001): 1150 mL (780-1496 mL) and 1579 mL (1313-2074 mL), respectively 
(Figure 7). 12 (15%) patients in the TXA group and 34 (39%) patients in the control group 
needed transfusion after the operation. The total number of transfused RBC units in the TXA 
group was 26 versus 82 units in the control group. The mean transfusion rate was significantly 
lower among the patients where perioperative tranexamic acid was used (0.32 unit (±0.09 unit) 
versus 0.94 unit (±0.15 unit), p=0.003). The intensity of surgical wound bleeding differed 
significantly between the two groups during the first postoperative 24 hours: 1.71 (±0.083) in 
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the control group versus 0.35 (±0.086) in the TXA group (p<0.001). The number of patients in 
the different wound bleeding categories in both groups are illustrated in Table 10. 
 
Table 10 Frequency chart of wound bleeding intensity. The intensity of wound bleeding in the 
postoperative 24 hours was significantly lower in the TXA group (p<0.001) compared to 
control group. Data are presented as number of patients and relative percentages in bracket. 
Definitions of categories are detailed in Table 2. 






0 64 (79.0%) 1 (1.1%) 
1 10 (12.3%) 39 (44.8%) 
2 3 (3.7%) 31 (35.6%) 








The extent of postoperative thigh swelling showed significant difference on the 7th 
postoperative day: 270.3 mL (129.1-449.0 mL) in the TXA group and 539.8 mL (350.0-864.8 
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mL) in the control group (p<0.001) (Figure 8). The area of haematoma was significantly smaller 
in the TXA group (0.64 (±0.21) vs. 2.46 (±2.13), p<0.001). The duration of serous wound 
discharge after drain removal had a tendency to be shorter in the TXA group (0.56 day (±0.97 
day)) compared to the control group (1.15 day (±1.86 day), which did not reach the statistical 
significance (p=0.064). 
 
Figure 8 Postoperative change in thigh volume. Significant thigh volume increase was found 






Without any prophylaxis the incidence of DVT ranges from 40% to 60% in patients after 
major orthopaedic operations [4, 5] and the incidence of fatal PE is 2% to 3% after elective hip 
replacement [6, 7]. Despite decades of clinical experience and a plethora of studies, the ideal 
method of VTE prophylaxis remains controversial. Thromboprophylaxis reduces the risk of 
VTE (including fatal PE) by more than 60% [24]. 
During the last few decades, based on clinical trials, experiences and guidelines, LMWHs 
have become the standard thromboprophylactic drugs in orthopaedics [36]. Enoxaparin, is still 
one of the most favoured subcutaneously administered antithrombotic agent in Europe, thus 
logically it was used as the comparator during clinical trials with dabigatran etexilate. Trials 
with the new direct thrombin inhibitor investigated the major and clinically significant bleeding 
events as safety endpoints, however, minor bleeding events were mostly ignored and their exact 
details were unknown [49-52]. Table 11 shows collected bleeding complications of the relevant 
doses in the studies with dabigatran etexilate.  
The BISTRO I determined the safe therapeutic range of dabigatran etexilate following 
THR [52]. At the end of this study the lack of any major bleeding episodes and potentially 
higher number of minor bleeding events were explained by the inaccurately defined bleeding 
complication criteria.  
Different doses of dabigatran were compared during BISTRO II study [49]. The higher 
doses of dabigatran were significantly more effective than enoxaparin, although also resulted 
in increased bleeding events.  
The RE-NOVATE study declared that 150 mg or 220 mg doses of dabigatran etexilate 
are as effective as 40 mg enoxaparin for the prevention of venous thromboembolism, with a 
similar safety profile [50]. 
RE-NOVATE II study found similar risk of bleeding and safety profiles in the 220 mg 
dabigatran etexilate group and the 40 mg enoxaparin groups after THR [51]. Minor and 
clinically relevant non-major bleeding was highlighted in this study, as summarized results, 
which showed a raised incidence of minor wound complications using dabigatran etexilate. 
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Table 11 Comparable bleeding events during the treatment periods of each study. Data are 
n (%). *For all bleeding outcomes, none of the differences between each dabigatran etexilate 
dose and enoxaparin were significant. +Starting with a half dose 1-4 hours postoperatively. 














BISTRO I     
Dabigatran 50 mg bid 30 0 n.a. 2 (7.4%) 
Dabigatran 150 mg bid 29 0 n.a. 26 (89.7%) 
Dabigatran 300 mg qd 46 0 n.a. 41 (89.1%) 
BISTRO II     
Dabigatran 50 mg bid 265 0 5 (1.9%) 11 (4.2%) 
Dabigatran 150 mg bid 266 10 (3.8%) 11 (4.1%) 23 (8.6%) 
Dabigatran 300 mg bid 258 12 (4.7%) 12 (4.7%) 22 (8.5%) 
Enoxaparin 40 mg qd # 270 6 (2.2%) 7 (2.6%) 14 (5.2%) 
RE-NOVATE     
Dabigatran 220 mg qd*+ 1146 23 (2.0%) 48 (4.2%) 70 (6.1%) 
Dabigatran 150 mg qd*+ 1163 15 (1.3%) 55 (4.7%) 72 (6.2%) 
Enoxaparin 40 mg qd # 1154 18 (1.6%) 40 (3.5%) 74 (6.4%) 
RE-NOVATE II     
Dabigatran 220 mg qd*+ 1010 14 (1.4%) 23 (2.3%) 61 (6.0%) 
Enoxaparin 40 mg qd # 1003 9 (0.9%) 20 (2.0%) 54 (5.4%) 
 
Enoxaparin exhibits predictable anticoagulation and can be given at fixed doses, but 
subcutaneous administration limits its use in the outpatient setting. Disadvantages include an 
indirect method of action, risk of HIT, allergic reactions due to its animal origin and a short 
elimination half-life [83]. If necessary, the possibility of monitoring the thrombocyte count and 
the efficacy through the aPTT exist and administration of protamine sulphate is available as an 
antidote [7, 84]. 
Dabigatran etexilate is just as effective and safe as LMWHs, furthermore it does not have 
the above mentioned disadvantages. However, it lacks the option of monitoring [7, 84, 85]. In 
2016 idarucizumab was announced as a specific antidote for the immediate reversal of 
dabigatran. It is indicated when rapid reversal of the anticoagulant effects of dabigatran etexilate 
is required for emergency surgery/urgent procedure or life-threatening or uncontrolled bleeding 
[86]. 
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Our clinical experiences with elevated serous wound discharge enticed us to explore the 
background of the bleeding profile of dabigatran focusing on minor bleeding events and design 
a study to prove our clinical observations. No previous similar detailed reports are available 
with dabigatran on the minor, but clinically important, potentially detrimental side effects of 
haematoma around the operated area (oozing from the wound and prolonged discharge from 
the drain site). A previous study in the United Kingdom found a significant, delayed wound 
discharges after taking dabigatran postoperatively. Based on their study they no longer 
administer dabigatran from the day of surgery but prefer to start the VTE prophylaxis with 
dalteparin (LMWH) until the wound is dry postoperatively and then discharge the patient home 
on oral dabigatran [72]. 
In our study the incidence of major and clinically significant bleeding events were higher 
in both groups compare to the dabigatran development trials [49-52], although the same 
previous guidelines were applied. Patients were equally divided and operated by seven 
experienced orthopaedic surgeons using the same surgical technique. No significant differences 
were seen in terms of individual complication rates amongst the surgeons.  
Although our study involved a relatively small number of patients, we have managed to 
find significant differences in serous wound discharge. No such differences were found in terms 
of skin haematoma formation. Only a few studies examined the wound complication rate using 
dabigatran, our study was among the first ones [72, 87-89]. Our aim was not to establish the 
pharmacological explanation for minor bleeding complications. We can only hypothesise that 
the relatively early postoperative administration of dabigatran (starting with a half dose 1-4 
hours after surgery), might be responsible for the increased incidence of postoperative wound 
ooze. The current ACCP guidelines recommend to start LMWH as thromboprophylaxis either 
12 hrs or more preoperatively or 12 hrs or even later postoperatively rather than within 4 hrs or 
less preoperatively or 4 hrs or less postoperatively [7, 27]. Also there are publications about an 
elevated incidence of bleeding complications and wound infection using rivaroxaban [13, 73]. 
We found the same, statistically significant increase in thigh volume in both our groups 
between the initial and 7th postoperative day data, without any difference in thigh volumes with 
the two different anticoagulants. These increased thigh volumes might be caused by the normal 
wound healing processes which are regulated by local proinflammatory cytokines, growth 
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factors, tissue response processes and are also related to the hidden blood loss that might be 
present during major orthopaedic interventions. A recent study examined histologically the 
effect of enoxaparin, rivaroxaban and dabigatran on wound healing process using a rat model, 
and found neither beneficial nor harmful effect of them on wound healing [90]. 
An early study in 1981 mentioned anticoagulant therapy causing wound haematoma and 
wound draining as risk factor of deep infection after THR [91]. It is still controversial whether 
a wound leakage can be an important source of late periprosthetic infection [91, 92], however 
some authors observed positive correlation between discharge from the wound and late deep 
infection [93, 94]. The first report on minor, but clinically important side-effects found an 
increased incidence of bruising and prolonged discharge from the drain site after enoxaparin 
compared to control group without thromboprophylaxis [95]. The “clexane-knee” entity was 
well known over the early introductory period of enoxaparin. Minor bleeding complications 
caused reluctance in the use of LMWHs at that time [96]. A questionnaire based study of hip 
and knee surgeons found in 1997 that 48 % of surgeons had stopped using LMWHs because of 
bruising, ooze, bleeding problems and formation of haematoma [97]. Over the last two decades 
we have come to accept the minor side-effects of enoxaparin. The new dabigatran etexilate can 
potentially cause more prolonged oozing from the drain site and an increased incidence of 
serous wound discharge, which might prevent this agent from being widely used in orthopaedic 
surgery. Additional to this, it is unsafe to discharge a patient with an oozing wound or drain 
site, even when his/her postoperative state would otherwise allow this, which might lead to 
longer hospitalisation and prolonged use of antibiotics to prevent secondary contamination of 
the surgical site. This might increase the costs of perioperative care [98, 99]. 
Our first study has several strengths and weaknesses. It was performed in a single large 
volume tertiary referral university department, using consecutive patients, and a standardized 
surgical technique. The two compared groups were found to be demographically similar. 
Perioperative blood loss was monitored comprehensively (in theatre, calibrated drain canisters, 
Hb concentration, thigh volume monitoring, wound haematoma, drainage, serous discharge). 
Arguably our patient population is still relatively small, as establishing differences in 
reoperation or infection rate requires large multi-centre studies. We did use drains in primary 
THR patients, in both groups, which is although not unheard of, is relatively less common 
nowadays [100, 101]. The use of suction drains remains controversial after joint arthroplasty. 
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There is increasing evidence suggesting that drains are not routinely required as they do not 
have any proven positive effect [102-104]. Based on our findings and these publications we 




A handful of studies have examined peri- and postoperative bleeding after cemented THR 
with the use of tranexamic acid [65, 74, 105, 106]. Regarding cemented THR, the femoral canal 
and the acetabular bony beds are closed off by bone cement, and its pressurization has a ceasing 
effect on blood loss from the intramedullary circulation. Therefore, postoperative bleeding 
tends to be lower in cemented THR compared to cementless THR, which means that it is 
essential to examine the two types of prosthesis separately [107]. Our study was amongst the 
first few orthopaedic studies publishing results on the effect of TXA following THR when the 
new oral anticoagulant rivaroxaban was used for thromboprophylaxis [75, 108]. According to 
our knowledge, this study was the first prospective study examining the effect of TXA in 
primary cemented THR using rivaroxaban as thromboprohylaxis and focusing on minor 
bleeding and wound leakage complications. 
Regarding cemented THR, the timing and dosage of TXA are still subject to an intense 
debate [63]. Previous studies used TXA in patients undergoing THR with doses of 10 or 15 
mg/kg with or without continuous infusion or in the form of a single 1 g bolus before surgery, 
and reported significantly lower amounts of blood loss both intra- and postoperatively [64-66, 
74, 106, 109, 110]. 10 mg/kg TXA before the incision was considered to produce a therapeutic 
blood concentration of 5 mg/L to 10 mg/L for three hours [106], which theoretically can reduce 
bleeding during surgery. The pharmacological effect of TXA is to delay fibrinolysis by blocking 
the lysine binding sites on the plasminogen molecule [65]. Theoretically, TXA has no influence 
on primary haemostasis and coagulation [111]. Other factors that affect intraoperative bleeding 
during THR may be related to the patient’s comorbidities, the surgeons’ commitment to 
intraoperative bleeding control, operating time and the method of anaesthesia [111]. With the 
respect to the timing of administration of TXA, Benoni et al. initially administered it at the end 
of the operation and then again 3 hours later, and could not find significant reduction of peri- 
and postoperative blood loss [105]. In contrast, Ekbäck at al. reported that TXA initially given 
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just before the surgical incision and a repeated dose 3 hours later significantly reduced peri- 
and postoperative blood loss in cemented THA [65]. In Hungary, the use of a daily dose of 500-
1000 mg intravenous TXA is approved for prophylaxis to prevent local fibrinolysis. 
According to a recently published meta-analysis, involving 1608 patients undergoing 
THR from 25 randomized controlled trials and reported on wound complications, the use of 
TXA leads to a slight reduction in the risk of developing wound complications compared to the 
control group [54]. We found the same, in our patients who received TXA, there was 
significantly reduced wound bleeding, a smaller frequency of wound dressing changes, and had 
a tendency to achieve a dry surgical wound earlier as compared with the control group. In the 
TXA group, the extent of thigh swelling was 50% less on the 7th postoperative day, which can 
be attributed to the reduced formation of a deep haematoma. Our study examined the superficial 
haematoma on the skin surface as well, which was significantly smaller in size when compared 
with the control group. In a previous double-blinded, randomized study, deep haematoma 
volumes were measured with ultrasonography on the 7th postoperative day in a group of patients 
receiving TXA and a control group not receiving TXA following THR [64]. The authors did 
not find a significant difference; however, the mean volume of haematoma was 28% smaller in 
their TXA group (270 mL (CI 209-331 mL) vs. 376 mL (CI 257-494 mL)). These findings can 
be explained by the pharmacological effect of TXA, as revealed in an early in vitro study, where 
the authors found that tranexamic acid inhibited clot lysis more efficiently when it was added 
before clot formation [112]. 
Previous studies have examined the factors which can cause prolonged wound healing 
and late periprosthetic infection. The postoperative haematoma formation and thigh swelling 
were found among the potential sources of infectious complications [93, 94]. A limitation of 
our study was a relatively small sample size, and therefore it was not powered to examine 
relatively rare complications such as periprosthetic joint infection. However, it provided 
evidence of a reduced presence of potential predisposing factors of infectious complications in 
patients receiving TXA. 
Our second study has several strengths and considerable limitations. It was performed in 
a single university department with a large surgical volume, enrolled consecutive patients, and 
used a standardized surgical technique. The two compared groups were demographically 
45 
similar and the number of patients was high enough to provide significant differences. 
Perioperative blood loss was monitored comprehensively via multiple end-points (i.e. 
intraoperative blood loss, drainage volume, Hb concentration, wound haematoma and drainage, 
duration of serous discharge). One of the limitations was the perioperative administration of a 
total of 1000 mg TXA, which is lower dose than what used in some of the prior studies. Despite 
this arguably low dose, we found a significantly reduced postoperative blood loss, transfusion 
rate and decreased wound bleeding in the TXA treatment group, suggesting sufficient serum 
levels. In line with this, there are previous studies showing that 1000 mg or even lower doses 
of TXA can effectively reduce blood loss and the postoperative transfusion requirement in THR 
[15, 63]. Arguably, our study did not use randomisation; however, the two groups were clearly 
separated in time, and the only variable distinguishing the two groups was the use of TXA. In 
addition to the demonstrated decrease in the need of transfusions, the decreased incidence of 
minor bleeding complications may have the potential to provide an additional benefit in 
reducing the frequency of delayed infectious complications. Further investigations and analyses 




The new findings of the above presented works can be summarized as the following: 
1. Increased incidence of prolonged discharge from the drain site and elevated 
serous wound discharge were found using dabigatran etexilate if compared with 
enoxaparine. 
2. The same amount of thigh volume increase was observed on the 7th postoperative 
day after THR with either enoxaparine, dabigatran or rivaroxaban. 
3. According to our knowledge, we reported the first clinical study examining the 
effect of perioperatively administered TXA in a well-defined subgroup of patients 
undergoing clearly cemented THR and anticoagulated postoperatively with 
rivaroxaban. 
4. The extent of thigh swelling was about 50% less on the 7th postoperative day, 
when TXA was used perioperatively during THR.  
5. In addition to the well-known perioperative blood loss and transfusion rate 
reducing effect, our results demonstrate a significant reduction of postoperative minor 
bleeding complications using multiple end-points when administering TXA, including 
blood loss through drain site, surgical wound bleeding, the size of superficial 
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